Literature DB >> 26301735

Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database.

Julien Bezin1,2,3,4, Pierre-Olivier Girodet1,2,4, Sahondra Rambelomanana1,5, Maëlys Touya1,4, Paul Ferreira1,4, Véronique Gilleron6, Philip Robinson1,5, Nicholas Moore1,2,3,4, Antoine Pariente1,2,3,4.   

Abstract

The objective of this study was to evaluate the performance of the ICD-10 (International Classification of Diseases and Related Health Problems, 10(th) Edition) coding in the French hospitalization database (PMSI) to identify acute coronary syndrome (ACS) occurrence. Eligible hospitalizations were those that occurred at the Bordeaux teaching hospitals between 1 January 2011 and 31 December 2011 and had one of the ICD-10 codes related to ischaemic heart diseases (I20 to I25, excluding I23 and I25.2). Among these, 100 hospitalizations were randomly selected; for each case, the ACS diagnosis was confirmed/excluded after medical file examination by an independent events validation committee and the performance of codes, and combinations of codes, to identify ACS was evaluated by calculating the positive predictive value (PPV). Of the individual codes, I20.0, I21 and I24 had the highest PPV; 100.0% for I24 (95%CI [15.8-100.0]); 90.0% for I21 (95%CI [76.3-97.2]); and 66.7% for I20.0 (95%CI [38.4-88.2]). The combination of I20.0 or I24 codes was able to identify 12 of the 56 validated ACS cases with a PPV of 70.6% (95%CI [44.0-89.7]), the combination of I21 or I24 identified 38 cases with a PPV of 90.5% (95%CI [77.4-97.3]), the combination of I20.0 or I21 identified 46 cases with a PPV of 83.6% (95%CI [71.2-92.2]), and the combination of I20.0, I21 or I24 identified 48 cases with a PPV of 84.2% (95%CI [72.1-92.5]). The combination of I20.0, I21 or I24 codes had the best performance to identify occurrence of ACS in the French hospitalization database.
© 2015 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  acute coronary syndrome; administrative data; positive predictive value; validation

Mesh:

Year:  2015        PMID: 26301735     DOI: 10.1111/fcp.12143

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  13 in total

1.  Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.

Authors:  Elias J Dayoub; Matthew Seigerman; Sony Tuteja; Taisei Kobayashi; Daniel M Kolansky; Jay Giri; Peter W Groeneveld
Journal:  JAMA Intern Med       Date:  2018-07-01       Impact factor: 21.873

2.  Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.

Authors:  Patrick Blin; Caroline Dureau-Pournin; Régis Lassalle; Jérémy Jové; Florence Thomas-Delecourt; Cécile Droz-Perroteau; Nicolas Danchin; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2017-05-05       Impact factor: 4.335

3.  Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.

Authors:  Nicholas Moore; Stéphanie Duret; Adeline Grolleau; Régis Lassalle; Vanessa Barbet; Mai Duong; Nicolas Thurin; Cécile Droz-Perroteau; Sinem Ezgi Gulmez
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

4.  Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.

Authors:  Patrick Blin; Laurent Fauchier; Caroline Dureau-Pournin; Frédéric Sacher; Jean Dallongeville; Marie-Agnès Bernard; Regis Lassalle; Cécile Droz-Perroteau; Nicholas Moore
Journal:  Stroke       Date:  2019-08-08       Impact factor: 7.914

5.  Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors.

Authors:  Benjamin Miao; Adrian V Hernandez; Mark J Alberts; Nicholas Mangiafico; Yuani M Roman; Craig I Coleman
Journal:  J Am Heart Assoc       Date:  2020-01-15       Impact factor: 5.501

6.  Cost-effectiveness of screening of coronary artery disease in patients with type 2 DIABetes at a very high cardiovascular risk (SCADIAB study) rational and design.

Authors:  Kamel Mohammedi; Nathalie Préaubert; Tanguy Cariou; Vincent Rigalleau; Ninon Foussard; Laurent Piazza; Céline Bairras-Martin; Thierry Couffinhal; Julien Bezin; Antoine Benard
Journal:  Cardiovasc Diabetol       Date:  2021-03-13       Impact factor: 9.951

7.  Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.

Authors:  Ingrid Hougen; Reid H Whitlock; Paul Komenda; Claudio Rigatto; Kristin K Clemens; Navdeep Tangri
Journal:  BMJ Open Diabetes Res Care       Date:  2021-12

8.  Retrospective validation of a machine learning clinical decision support tool for myocardial infarction risk stratification.

Authors:  Saarang Panchavati; Carson Lam; Nicole S Zelin; Emily Pellegrini; Gina Barnes; Jana Hoffman; Anurag Garikipati; Jacob Calvert; Qingqing Mao; Ritankar Das
Journal:  Healthc Technol Lett       Date:  2021-08-31

9.  The 2015 and 2016 terrorist attacks in France: was there a short-term impact on hospitalizations for cardiovascular disease?

Authors:  Edouard Chatignoux; Amélie Gabet; Elodie Moutengou; Philippe Pirard; Yvon Motreff; Christophe Bonaldi; Valérie Olié
Journal:  Clin Epidemiol       Date:  2018-04-13       Impact factor: 4.790

Review 10.  Validity of Acute Cardiovascular Outcome Diagnoses Recorded in European Electronic Health Records: A Systematic Review.

Authors:  Jennifer Davidson; Amitava Banerjee; Rutendo Muzambi; Liam Smeeth; Charlotte Warren-Gash
Journal:  Clin Epidemiol       Date:  2020-10-14       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.